Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers N > Headlines for Noven Pharmaceuticals Inc. > News item |
Noven on hold by Jefferies
Jefferies & Co., Inc. analyst David Windley rated Noven Pharmaceuticals, Inc. at hold after Novogyne's revenues were $4.6 million above the analyst's forecast. Noven beat consensus and Jefferies' earning-per-share estimate by 2 cents. Shares of the Miami pharmaceutical company were down 41 cents, or 2.17%, at $18.49 on volume of 356,387 shares versus the three-month running average of 188,697 shares. (Nasdaq: NOVN)
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.